PTO/SB/08a (08-03)
Appropriate ruse through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademan office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of

Complete if Known					
Application Number	10/663,010	_			
Filing Date	September 15, 2003				
First Named Inventor	Tim Clarot				
Art Unit	1616				
Examiner Name	TBA				
Attorney Docket Number	33205.0800				

$\mathbb{L}$				U.S. PA	TENT DOCUMENTS	
Exa	miner els	Cite No.1	Decument Number  2 Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A	95	Α	US- 2,115,848	05-03-1938	Stanco Incorporated	
401		В	US- 4,724,231	02-09-1988	Nastech Pharmaceutical, Inc.	
921	4CL	С	US- 4,883,660	11-28-1989	Thames Pharmacal Co., Inc.	
40	M	D	US- 4,970,240	11-13-1990	Schering Corporation	
971	<i>yu</i>	Е	US- 5,114,979	05-19-1992	Schering Corporation	
9571	1	F	US- 5,158,761	10-27-1992	Toko Yakuhin Kogyo KK	
411	W.	G	US- 5,215,739	06-01-1993	Toko Yakuhin Kogyo KK	
D.	1/	H	US- 5,240,694	08-31-1993	University of Virginia, et al.	
<b>47</b>	16	I	US- 5,248,501	09-28-1993	Parnell Pharmaceuticals	
<b>Pait</b>		J	US- 5,271,943	12-21-1993	Scott Health Care	
TIK.	1/1	K	US- 5,346,703	09-13-1994	Mediventures, Inc.	
1H	199	L	US- 5,478,565	12-26-1995	Warner-Lambert Company	
A)H	a	M	US- 5,492,937	02-20-1996	Pharmacia AB	
TO!	a)	N	US- 5,760,085	06-02-1998	The Procter & Gamble Company	
102	the state of	0	US- 5,785,988	07-28-1998	Fust	<u> </u>
904	96	P	US- 5,854.269	12-29-1998	Schering-Plough Healthcare, etc.	
124	gi	Q	US- 5,897,858	04-27-1999	Schering-Plough Healthcare, etc.	
'QH	ã	R	US- 5,908,619	06-01-1999	Minnesota Mining and Mfg. Co.	
DH	V.	S	US- 5,948,414	09-07-1999	Nouveau Technologies, Inc.	
W	A	T	US- 5,988,870	11-23-1999	Partsky	

Notronslation

				FOR	<u>EIGN PATENT DO</u>	CUMENTS		
Examiner	Cite	Foreign Patent Docum		cument	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
initials	No.1	Office	3 Number <sup>4</sup>	Kind <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	Τg
	ММ	DE-	2839793	A1	<del>-05-10-1979</del>	Teko Yakuhin Kogyo KK		
The	NN	EP	0 147 476	A1	07-10-1985	Toko Yakuhin Kogyo KK		
<b>T</b>	00	JP -	61068413	A2	04-08-1986	Lion Corp.		
OHan	PP	EP	0 275 054	A1	07-20-1988	Toko Yakuhin Kogyo KK		$\perp$
DHAG	QQ	EP	0 391 342	A1	10-10-1990	Toko Yakuhin Kogyo KK		
4	RR	JP	5124955	A2-	<del>- 05-21-1993</del>	Shiseide Co. Ltd.		
QHAR	SS	wo	94/00108	Al	01-06-1994	The Procter & Gamble Co.		
Dirah	TT	wo	94/05330	Al	03-17-1994	The Procter & Gamble Co.		
SHOT	υυ	wo	99/38492	Al	08-05-1999	Novartis Consumer Health		
Hm	vv	wo	00/10530	A1	03-02-2000	The Procter & Gamble Co.		

Examiner Signature Date Considered 11/20/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08e (08-03)
Appround ruse through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/663,010 INFORMATION DISCLOSURE Filing Date September 15, 2003 STATEMENT BY APPLICANT First Named Inventor Tim Clarot Art Unit 1616 (use as many sheets as necessary) **Examiner Name TBA** of 3 Attorney Docket Number 33205.0800 Sheet

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials	Cite No.1	Document Number  Property Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Mari	U	US- 6,080,783	06-27-2000	Gum Tech International, Inc.	
OKE	V	US- 6,090,403	07-18-2000	LecTec Corporation	
BHAR	W	US- 6,143,329	11-07-2000	Rorer Pharmaceutical Products	
Digo	X	US- 6,235,312 B1	05-22-2001	Eastman Chemical Company	
Alla	Y	US- 6,316,483 B1	11-13-2001	Schering Corporation	
OVA	Z	US- 6,375,984 B1	04-23-2002	Rorer Pharmaceuticals Products	
Willer.	AA	US- 6,391,294 B1	05-21-2002	Reckitt Benckiser Healthcare	
OFFI	BB	US- 2001/0044411 AI	11-22-2001	Gelber, et al.	
One	CC	US- 2001/0053775 A1	12-20-2001	Seidel, et al.	
VHU	DD	US- 2002/0006961 A1	01-17-2002	Katz, et al.	
HAPT	EE	US- 2002/0012688 A1	01-31-2002	Dohi, et al.	
104499	FF	US- 2002/0022052 A1	02-21-2002	Dransfield	
11/201	GG	US- 2002/0037297 AI	03-28-2002	Crespo, et al.	
OXI	нн	US- 2002/0128273 Al	09-12-2002	Gelber, et al.	
OHOR	II	US- 2002/0172644 A1	11-21-2002	Haslwanter, et al.	
Dian	IJ	US- 2002/0193417 Al	12-19-2002	Seidel, et al.	
altan	KK	US- 2002/0197212 A1	12-26-2002	Osbakken, et al.	
ay hu	LL	US- 2003/0031631 A1	02-13-2003	Osbakken, et al.	
		US-			
		US-			

l				FUR	EIGN PATENT DO	CUMENIS		
Examiner Initials*		Office	Foreign Patent Do Number <sup>4</sup>	Kind <sup>5</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T8
	ww	wo.	.00/78297	A2	12-28-2000	Boohringer Ingelheim Int'l		+
								I
	<del> </del>						· · · · · · · · · · · · · · · · · ·	┼
	ļ	-						┿
	<del> </del>	-	<del></del>					+-
	-	<del> </del>	<del></del>		<del></del>			十一
		<del>                                     </del>						1
	i	1						T

EODEICH DATENT DOCUMENTS

Examiner Signature Considered 11/20/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (op8onal). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/088 (08-03)
App for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number,

ن ، ، ، ، ، ،

Substitu	ite for form 1449B/P	סדי		Complete if Known		
****			1001 001155	Application Number	10/663,010	
INFO	JRMATIO	ט אינ	ISCLOSURE	Filing Date	September 15, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Tim Clarot	
• • • • • • • • • • • • • • • • • • • •				Art Unit	1616	
	(use as man	y sheet	s as necessary)	Examiner Name	TBA	
Sheet	Sheet 3 of 3		Attorney Docket Number	33205.0800		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
م بلاره	Examiner Initials'	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the artic item (book, magazine, journal, serial, symposium, catalog, etc.), date, publisher, city and/or country where publi	page(s), volume-issue number(s),	T2				
Not provided.		xx	Abstract: ABD EL-BARY, A., et al.; "Bioavailability of Glibencla Pharmazeutische Industrie (1991), 53 (12), pgs. 1151-55	mide From Nasal Delivery Systems";					
-		YY-	Abstract: WASICKO M.I. et al.: "The Role of Vascular Tone in a Collapsibility"; American Review of Respiratory Disease (June 1996)	the Control of Upper Airway 90), 141 (6), pgs. 1569-77					
<b>√</b> <		22	Abstract: KUMAR, V., et al., "Aqueous ve Viscous Phenylephrine (August 1986), 104 (8), pgs. 1189-91	; Archives of Opthalmology					
			•						
			·						
	Examine	r		Date	=				
	Signatur	e		Considered	_)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.